Telix Pharmaceuticals to Acquire ITM Isotope Technologies Munich
September 21, 2026
Telix Pharmaceuticals signed an agreement to acquire 100% of ITM Isotope Technologies Munich for $1.65 billion upfront, plus up to $700 million in contingent payments tied primarily to regulatory approvals and sales milestones for ITM-11. The deal combines Telix’s radiopharmaceutical development and commercial platform with ITM’s isotope manufacturing, distribution network, and therapeutic pipeline; it remains subject to shareholder and regulatory approvals.
- Targets
- ITM Isotope Technologies Munich
- Sellers
- ITM shareholders
- Industry
- Pharmaceuticals
- Location
- Bavaria, Germany
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals
April 24, 2026
Biotechnology
Telomir Pharmaceuticals completed its previously announced stock-for-stock acquisition of TELI Pharmaceuticals. The deal makes Telomir the sole holder of global rights to Telomir-1 (Telomir-Zn), consolidating worldwide development and commercialization under one structure.
-
Telix Pharmaceuticals to Acquire RLS (USA) to Expand North American Radiopharmacy Manufacturing and Distribution
September 22, 2024
Healthcare Services
Telix Pharmaceuticals Limited has agreed to acquire RLS (USA) Inc. from its parent company, RLS Group Ltd., to expand Telix’s North American radiopharmaceutical manufacturing and distribution platform. The deal leverages RLS’s 31 Joint Commission-accredited radiopharmacies to build a radiometal production and distribution network and improve capacity for PET, SPECT, and therapeutic isotopes.
-
Telix Pharmaceuticals Acquires ARTMS Inc.
March 5, 2024
Pharmaceuticals
Telix Pharmaceuticals Limited has completed the acquisition of ARTMS Inc., a Burnaby, British Columbia-based developer of cyclotron-based isotope production technology and the QUANTM Irradiation System (QIS). The deal strengthens Telix's vertical integration and supply-chain control for key diagnostic and therapeutic radioisotopes (including 89Zr, 68Ga, 99mTc and 64Cu) to support its commercial products and pipeline.
-
Telix Pharmaceuticals Acquires QSAM Biosciences
February 8, 2024
Biotechnology
Telix Pharmaceuticals Limited has entered into an agreement to acquire QSAM Biosciences, Inc., adding QSAM's lead radiopharmaceutical candidate 153Sm-DOTMP (Samarium-153-DOTMP) to Telix's therapeutic pipeline. The asset expands Telix's oncology focus into bone-targeting radiopharmaceuticals with potential applications in pain management of bone metastases and osteosarcoma (including pediatric indications).
-
Temasek-Led €255M Investment Round in ITM Isotope Technologies Munich SE
June 5, 2023
Biotechnology
Temasek led a €255 million equity investment round in ITM Isotope Technologies Munich SE, with participation from QIA, BlackRock Alternatives, Nextech, ATHOS and Carbyne. The proceeds (mostly primary capital with a minority secondary component) will advance ITM's targeted radionuclide therapy pipeline, support late-stage clinical development of ITM-11, and expand GMP manufacturing capacity for n.c.a. 177Lu and 225Ac while bolstering commercial infrastructure.
-
Teledyne Technologies to Acquire ETM-Electromatic
October 26, 2022
Medical Devices
Teledyne Technologies Incorporated has entered into an agreement through a wholly-owned subsidiary to acquire ETM-Electromatic, Inc. (ETM). ETM designs and manufactures high-power microwave and high-energy X-ray subsystems used in cancer radiotherapy, defense, and X-ray security applications.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.